Here’s what you should know:
1. Patients will have access to clinical trials and to treatments they might not have previously had.
2. The Gastroenterology Group partnered with Elligo after recognizing the importance of allowing patients access to such treatments.
3. Emil Valle, MD, said, “As a practice on the forefront of medicine, we are pleased to be able to offer clinical trials as treatment options for our patients. This will give our patients access to novel therapies that they would otherwise not have.”
4. Elligo CEO John Potthoff, PhD, said the clinical research and related infrastructure is provided to the practice at no cost, so practice physicians can “focus on taking care of patients.”
5. Elligo reports 97 percent of U.S. physicians do not offer patients access to clinical research.
More articles on gastroenterology:
5 key observations on NJ ASC landscape post-‘One-Room Bill”
To prevent the spread of norovirus at the Olympics, athletes told to fist-bump, not shake hands: 4 things to know
Partner at Seaside Surgery Center receives board certification — 4 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
